XML 24 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Stockholders' Deficit - USD ($)
$ in Thousands
Common Stock
Previously reported
Common Stock
Revision of prior period, adjustment
Common Stock
Additional Paid-in Capital
Previously reported
Additional Paid-in Capital
Revision of prior period, adjustment
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Previously reported
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Previously reported
Accumulated Deficit
Previously reported
Total
Balance as at beginning at Dec. 31, 2021                       $ 382,288
Balance as at beginning (in shares) at Dec. 31, 2021                       73,259,663
Increase (Decrease) in Redeemable Convertible Preferred Stock [Roll Forward]                        
Accretion of Series G redeemable convertible preferred stock to redemption amount                       $ 2,237
Conversion of redeemable convertible preferred stock to common stock                       $ (384,525)
Conversion of redeemable convertible preferred stock to common stock (in shares)                       (73,259,663)
Balance as at beginning at Dec. 31, 2021     $ 13     $ 13,682   $ (3,445)   $ (498,536)   $ (488,286)
Balance as at beginning (in shares) at Dec. 31, 2021     13,183,259                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Accretion of Series G redeemable convertible preferred stock to redemption amount                   (2,237)   (2,237)
Conversion of redeemable convertible preferred stock to common stock     $ 74     384,451           384,525
Conversion of redeemable convertible preferred stock to common stock (in shares)     73,203,888                  
Common stock dividends issued to Series C and Series G redeemable convertible preferred stock     $ 29     (29)            
Common stock dividends issued to Series C and Series G redeemable convertible preferred stock (in shares)     28,685,582                  
Issuance of common stock upon exercise of stock options     $ 2     49           51
Issuance of common stock upon exercise of stock options (in shares)     2,459,014                  
Issuance of common stock from conversion of convertible promissory notes and accrued interest     $ 10     35,820           35,830
Issuance of common stock from conversion of convertible promissory notes and accrued interest (in shares)     10,228,522                  
Stock-based compensation           17           17
Foreign currency translation adjustment               1,583       1,583
Net income (loss)                   (26,412)   (26,412)
Balance as at end at Dec. 31, 2022 $ 128 $ (126) $ 2 [1] $ 433,990 $ 126 434,116 [1] $ (1,862) (1,862) [1] $ (527,185) (527,185) [1] $ (94,929) $ (94,929) [1]
Balance as at end (in shares) at Dec. 31, 2022 127,761,000 (103,900,000) 23,861,000 [1]                 127,760,265
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of common stock upon exercise of stock options [1]           1           $ 1
Issuance of common stock upon exercise of stock options (in shares) [1]     5,000                  
Stock-based compensation [1]           2           2
Foreign currency translation adjustment               674       674
Net income (loss)                   (1,393)   (1,393)
Balance as at end at Mar. 31, 2023 [1]     $ 2     434,119   (1,188)   (528,578)   (95,645)
Balance as at end (in shares) at Mar. 31, 2023 [1]     23,866,000                  
Balance as at beginning at Dec. 31, 2022 $ 128 $ (126) $ 2 [1] 433,990 126 434,116 [1] (1,862) (1,862) [1] (527,185) (527,185) [1] (94,929) $ (94,929) [1]
Balance as at beginning (in shares) at Dec. 31, 2022 127,761,000 (103,900,000) 23,861,000 [1]                 127,760,265
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Accretion of Series G redeemable convertible preferred stock to redemption amount                       $ 0
Issuance of common stock upon exercise of stock options     $ 1     22           23
Issuance of common stock upon exercise of stock options (in shares)     1,130,481                  
Issuance of common stock from conversion of convertible promissory notes and accrued interest           72           72
Issuance of common stock from conversion of convertible promissory notes and accrued interest (in shares)     20,681                  
Issuance of common stock from cancellation of promissory note     55,775                  
Issuance of common stock from warrant exercise           1,499           1,499
Issuance of common stock from warrant exercise (in shares)     428,572                  
Stock-based compensation           43           43
Foreign currency translation adjustment               324       324
Net income (loss)                   (22,469)   (22,469)
Balance as at end at Dec. 31, 2023 $ 129 $ (126) $ 3 [1] $ 435,626 $ 126 435,752 [1] $ (1,538) (1,538) [1] $ (549,654) (549,654) [1] $ (115,437) $ (115,437) [1]
Balance as at end (in shares) at Dec. 31, 2023 129,395,774 (105,230,000) 24,166,000 [1]                 24,166,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Reverse recapitalization transaction, net of transaction costs and acquired liabilities     $ 2     50,031           $ 50,033
Reverse recapitalization transaction, net of transaction costs and acquired liabilities (in shares)     21,667,000                  
Stock-based compensation           1,223           1,223
Foreign currency translation adjustment               1,064       1,064
Net income (loss)                   757   757
Balance as at end at Mar. 31, 2024     $ 5     $ 487,006   $ (474)   $ (548,897)   $ (62,360)
Balance as at end (in shares) at Mar. 31, 2024     45,833,000                 45,833,000
[1] Amounts as of December 31, 2023 differ from those in prior year consolidated financial statements as they were retrospectively adjusted as a result of the accounting for the Business Combination (as defined in the Notes to the Unaudited Condensed Consolidated Financial Statements.)